Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals (Nasdaq: OLMA) has granted stock options to one new employee as part of its inducement program. The grant includes options to purchase 2,500 shares of common stock at an exercise price of $11.62 per share. The options vest over four years, with 25% vesting after the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals (Nasdaq: OLMA) ha concesso opzioni su azioni a un nuovo dipendente come parte del suo programma di incentivazione. La concessione include opzioni per l'acquisto di 2.500 azioni ordinarie a un prezzo di esercizio di $11,62 per azione. Le opzioni maturano nell'arco di quattro anni, con il 25% che matura dopo il primo anno e il restante che matura mensilmente per tre anni. Le opzioni hanno una durata di 10 anni e sono state concesse nell'ambito del Piano di Incentivazione 2022 della società, in conformità con la Regola di Listaggio Nasdaq 5635(c)(4).
Olema Pharmaceuticals (Nasdaq: OLMA) ha otorgado opciones sobre acciones a un nuevo empleado como parte de su programa de incentivo. La concesión incluye opciones para comprar 2,500 acciones ordinarias a un precio de ejercicio de $11.62 por acción. Las opciones se consolidan durante cuatro años, con el 25% consolidándose después del primer año y el resto consolidándose mensualmente durante tres años. Las opciones tienen un plazo de 10 años y se otorgaron bajo el Plan de Incentivo 2022 de la empresa, de acuerdo con la Regla de Listado Nasdaq 5635(c)(4).
Olema Pharmaceuticals (Nasdaq: OLMA)는 유인 프로그램의 일환으로 신규 직원에게 주식 옵션을 부여했습니다. 이 부여에는 2,500주의 보통주를 주당 $11.62의 행사 가격으로 매입할 수 있는 옵션이 포함되어 있습니다. 옵션은 4년에 걸쳐 발생하며, 첫 해에 25%가 발생하고 나머지는 3년에 걸쳐 매월 발생합니다. 옵션의 유효 기간은 10년이며, Nasdaq 상장 규칙 5635(c)(4)에 따라 회사의 2022 유인 계획에 따라 부여되었습니다.
Olema Pharmaceuticals (Nasdaq: OLMA) a accordé des options sur actions à un nouvel employé dans le cadre de son programme d'incitation. La concession comprend des options d'achat de 2 500 actions ordinaires à un prix d'exercice de 11,62 $ par action. Les options acquièrent des droits sur une période de quatre ans, avec 25 % acquérant des droits après la première année et le reste acquérant des droits mensuellement pendant trois ans. Les options ont une durée de 10 ans et ont été accordées dans le cadre du Plan d'Incentivation 2022 de l'entreprise, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Olema Pharmaceuticals (Nasdaq: OLMA) hat einem neuen Mitarbeiter im Rahmen seines Anreizprogramms Aktienoptionen gewährt. Die Gewährung umfasst Optionen zum Erwerb von 2.500 Aktien zu einem Ausübungspreis von 11,62 $ pro Aktie. Die Optionen werden über einen Zeitraum von vier Jahren fällig, wobei 25 % nach dem ersten Jahr und der Rest monatlich über drei Jahre erfolgt. Die Optionen haben eine Laufzeit von 10 Jahren und wurden im Rahmen des Anreizplans 2022 des Unternehmens gemäß der Nasdaq-Listenregel 5635(c)(4) gewährt.
- None.
- None.
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to one new employee to purchase an aggregate of 2,500 shares of the Company's common stock, effective as of November 1, 2024. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of November 1, 2024, as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
IR and Media Contact
Courtney O’Konek, Vice President, Corporate Communications
media@olema.com
FAQ
What stock options did Olema Pharmaceuticals (OLMA) grant on November 1, 2024?
What is the vesting schedule for OLMA's November 2024 stock option grant?
What was the exercise price for OLMA's November 2024 inducement grant?
